Events Archives - Page 26 of 128

2 minute read

Monte Rosa Therapeutics Presents Preclinical Data At ACR Convergence 2023 Demonstrating Potential Of MRT-6160, A VAV1-Targeted Molecular Glue Degrader, To Treat Immunological And Inflammatory Diseases

November 7, 11:01 AM

Data presented support broad potential therapeutic applications of MRT-6160 in a variety of autoimmune and inflammatory disorders driven by underlying dysregulation of T- and B-cells, including rheumatoid

GLUE

3 minute read

First Data For ImmunityBio’s Memory Cytokine-Enriched NK Cells In Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity

By Benzinga Newsdesk

November 7, 10:06 AM

Findings from NCI-led study suggest that Memory Cytokine-Enriched Natural Killer cells (M-ceNK) may provide benefit to patients with small cell lung cancer and patients with other types of neuroendocrine tumors

IBRC

2 minute read

Novo Nordisk To Present New Cardiometabolic Disease Data, Including Results From Select, At The Annual American Heart Association Scientific Sessions

By Benzinga Newsdesk

November 7, 9:44 AM

SELECT and STEP HFpEF phase 3 trials explore obesity and cardiovascular disease in adultsAWARE study evaluates existing treatment gaps in adults with type 2 diabetes living with overlapping conditionsPLAINSBORO, N.J.,

NVO

2 minute read

Vistagen To Present Fasedienol Phase 3 Data And PH80 Phase 2A Data At Upcoming Scientific Conferences

By Benzinga Newsdesk

November 7, 9:35 AM

Positive top-line results from fasedienol (PH94B) Phase 3 PALISADE-2 trial in social anxiety disorder (SAD) to be presented by SAD expert, Dr. Michael Liebowitz, at CNS Summit 2023Positive results from PH80 Phase 2A

VTGN

2 minute read

Aligos Therapeutics To Present Multiple Posters At AASLD’s The Liver Meeting 2023, Highlighting Progress For Its Clinical Stage Portfolio, including Lead THR-β Agonist For The Treatment Of NASH, ALG-055009; ALG-000184, The Company’s Lead CAM-E Molecule

By Benzinga Newsdesk

November 7, 9:08 AM

Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that

ALGS

4 minute read

Inventiva Announces A Late Breaker Abstract And Two Additional Abstracts On Its Lead Compound, Lanifibranor, At The AASLD The Liver Meeting 2023

By Benzinga Newsdesk

November 6, 6:30 PM

The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating

IVA

1 minute read

Akari Therapeutics To Present A Poster On Pre-Clinical Development Of Long-Acting PAS-Nomacopan As A Potential Treatment For Geographic Atrophy At The 4th Annual Dry AMD Therapeutic Development Conference

By Benzinga Newsdesk

November 6, 9:49 AM

Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Chief Scientific Officer Miles Nunn will present a

AKTX

2 minute read

IN8bio Presents Biologic Correlative Data From The INB-200 Phase 1 Trial In Newly Diagnosed Glioblastoma At The Society For Immunotherapy Of Cancer 38th Annual Meeting

By Benzinga Newsdesk

November 6, 9:47 AM

Data demonstrate the ability of single and repeat doses of INB-200, DeltEx drug-resistant immunotherapy (DRI) gamma-delta T cell therapy, to induce T cell persistence and a sustained immune response. A treated

INAB

3 minute read

Kineta Unveils New Data From VISTA-101 Clinical Trial Of KVA12123 At The Society For Immunotherapy Of Cancer’s 38th Annual Meeting

By Benzinga Newsdesk

November 6, 9:34 AM

Favorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines Achieved Greater Than Dose-Proportional PharmacokineticsBiomarker Results Demonstrate Robust VISTA Target

6 minute read

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data From The Ongoing Phase 1 Study Of ELI-002 And New Preclinical Data On ELI-007 And ELI-008 At The Society For Immunotherapy Of Cancer Annual Meeting

By Benzinga Newsdesk

November 3, 4:31 PM

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vaccine, as monotherapy, 87% (20/23) had direct ex vivo mKRAS-specific T

ELTX